Forbes has highlighted the development work of Sangamo BioSciences, which has a "hefty" pipeline of drug candidates in development that use zinc-finger DNA binding proteins to manipulate genes for a number of diseases which currently can't be treated. Report [1]
Links:
[1] http://www.forbes.com/technology/2008/05/14/gene-therapy-sangamo-tech-science-cz_kad_0514gene.html